Home > Healthcare > Drug Device Combination > Therapeutic Systems > Cervical Dysplasia Market

Cervical Dysplasia Market Size

  • Report ID: GMI9898
  • Published Date: Jun 2024
  • Report Format: PDF

Cervical Dysplasia Market Size

Cervical Dysplasia Market size was valued at USD 675.5 million in 2023 and is estimated to grow at 7.1% CAGR from 2024 to 2032, due to the increasing prevalence of human papillomavirus (HPV) infections, which are closely linked to the development of cervical dysplasia.

 

For instance, according to the International Agency for Research on Cancer, the global prevalence of HPV infection in women with normal cytology is around 11-12%, with the highest rates in sub-Saharan Africa (24%), Eastern Europe (21%), and Latin America (16%). Thus, as more women are diagnosed with cervical dysplasia resulting from HPV, there is a growing demand for effective screening, diagnostic, and treatment options. Moreover, advancements in diagnostic technologies and the development of effective vaccines against high-risk HPV strains further boost the market growth.
 

Cervical dysplasia is a medical condition characterized by the presence of abnormal cells on the surface of the cervix. These changes are not cancerous but can be considered precancerous, meaning they have the potential to develop into cervical cancer if left untreated. Cervical dysplasia is often detected through routine screening methods such as Pap smears or HPV DNA tests. It is commonly caused by persistent infection with high-risk types of HPV. Treatment options vary depending on the severity of the dysplasia and may include surgical procedures, and non-surgical procedures.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cervical dysplasia market size was USD 675.5 million in 2023 and is expected to register 7.1% CAGR from 2024-2032 owing to the increasing prevalence of human papillomavirus (HPV) infections, which are closely linked to the development of cervical dysplasia worldwide.

Cervical dysplasia industry from the low-grade cervical dysplasia segment is expected to register 7.2% CAGR from 2024-2032 due to its higher prevalence compared to high-grade dysplasia.

The U.S. cervical dysplasia industry reached USD 272.1 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to advanced healthcare infrastructure, high prevalence of HPV infections, and widespread cervical cancer screening programs in the region.

Abbott Laboratories, Asieris Pharmaceuticals, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hologic Inc., Kinopharma, Merck & Co., Inc., OncoHealth Corporation, and Qiagen, are some of the major cervical dysplasia companies worldwide.

Cervical Dysplasia Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 292
  • Countries covered: 22
  • Pages: 160
 Download Free Sample